GH001 Shows Durable Remission in Depression—Over 70% at Six Months
GH Research PLC is taking a significant leap in the race to treat depression where other therapies have failed. The company’s lead candidate, GH001, just wrapped up a Phase 2b trial targeting treatment-resistant depression (TRD), not only meeting its primary clinical endpoint but delivering durable results: 73% of patients achieved remission at six months with minimal retreatment and no mandated psychotherapy.
Presented at leading psychopharmacology congresses in 2025, the data show a placebo-adjusted Montgomery-Åsberg Depression Rating Scale (MADRS) reduction of –15.5 points at Day 8 (p<0.0001). In context: 57.5% on GH001 achieved remission (MADRS =10) versus 0% on placebo. The ultra-rapid—~11-minute—psychoactive effect meant 99% of patients were ready for discharge within an hour, with no serious side effects or emergent suicidality recorded.
FDA Greenlight and Pivotal Phase 3 on the Horizon
Perhaps just as notable, the FDA has cleared GH001 for U.S. clinical investigation, opening the door to enrollment for stateside patients. GH Research is actively working with the FDA to finalize the design of its global Phase 3 program, aiming to replicate the notable results observed in Phase 2b. The pivotal program is expected to launch in 2026, with the company preparing its proprietary aerosol delivery device to support the expansion.
Strength in Numbers: Financial Position Bolsters Expansion Plans
Beyond the clinic, GH Research’s financial health stands out. As of December 31, 2025, the company reported $280.7 million in cash, cash equivalents, and marketable securities, up sharply from $182.6 million the prior year. This strong cash runway is critical to funding the costly global clinical program now underway.
| Key Financials (USD, thousands) | 2025 | 2024 |
|---|---|---|
| Cash, Equivalents & Securities | $280,708 | $182,624 |
| R&D Expenses | $(38,765) | $(35,016) |
| G&A Expenses | $(21,953) | $(15,296) |
| Net Loss | $(48,258) | $(38,961) |
| Loss per Share | $(0.79) | $(0.75) |
Operating expenses increased year-over-year, reflecting ongoing technical and staffing investments as the company readies for pivotal Phase 3 activity. Despite a widening net loss, the company’s cash position gives it plenty of room to maneuver for the next stage of development.
Durability and Safety Could Shape a New Paradigm in TRD
Perhaps the most compelling angle: GH001’s prolonged efficacy and benign safety profile without mandatory psychotherapy sets it apart from other approaches. The company’s ability to achieve high remission rates with brief, infrequent administration could change the way clinicians approach TRD, should Phase 3 results replicate these findings.
For observers and investors, GH Research’s next milestones come with the kick-off of global Phase 3 trials and regulatory milestones in the U.S. If the results keep pace with the latest data, the market for depression treatment could soon have a transformative new contender.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI